retatrutide phase 2 trial Great news again!!! A of (Triple–Hormone-Receptor Agonist) for obesity. At 48 wks the median body weight loss was 24.2% and >5%, >10% and >15% had occurred in 100% Retatrutide Shows Promising Results in
Description
Due to confounding and the pharmacovigilance analytical approach used, causality is inconclusive
This study highlights the importance of considering both the benefits and drawbacks of using GLP-1 agonists
Common side effects include nausea, vomiting, diarrhea, and constipation, typically mild and temporary
monitor lipid levels
Available at: Review Articles and Broader Context Kaiser Family Foundation
Patients should maintain realistic expectations and understand that GLP-1 medications work best when combined with dietary modifications and increased physical activity
